Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > House 83 Accumulates Again

<< Previous

Bullboard Posts

Next >>

Comment by 2019champson Jun 19, 2023 10:36pm

78 Views

Post# 35504418

RE:House 83 Accumulates Again

Arch is due for news at any point now. Phase 2 Data, and initiation of the AKI trial will be huge milestones. Double digit share price this year isn't far fetched considering where peer groups are trading.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments